Insider buying last 90 days
No open-market insider purchases were filed for COR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every COR insider filing, plotted on the chart in Gekko.Open COR in Gekko
NYSE: COR
Cencora (COR) Stock Analysis & Forecast
Nov 4 close
$354.00+13.50 (+4.0%)
Gekko Brief
AI summaryNov 4 closeCencora moves this week on fiscal fourth-quarter results and forward guidance. The company reported fiscal Q4 2026 earnings with net income of $519.4 million, or $2.71 per share, adjusted earnings of $4.66 per share, and revenue of $88.35 billion, topping Wall Street estimates on higher specialty pharmaceutical volumes, GLP-1 drug demand, and the OneOncology acquisition. Alongside the beat, Cencora issued fiscal 2027 adjusted EPS guidance of $19.40 to $19.75, below the $19.70 consensus estimate, and announced a realignment of its corporate and reporting structure into two operating segments, including a Specialty Pharmaceutical and Provider Services unit led by Richard Tremonte.
The stock closed at $354.00, up 4%, and sits above both its 50-day average of $324.63 and 200-day average of $316.94, with the shorter average above the longer one. The GekkoIndex reads 43.1, placing it in the Distribution zone, down from a five-day change of -16.1. Against this, the price sits 19.3% below the Gekko Fair Value of $438.84.
No confirmed earnings date is on the calendar following this report. Over the last 90 days, Congressional activity shows 1 buy and 0 sales, while billionaire holders stand at 0. Seasonality over the next 20 trading days has averaged a 1.3% return across 5 years, rising in 3 of them. Analyst coverage includes 11 buy ratings, 2 hold, and 0 sell among 13 firms, with a consensus target of $371.67.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Cencora price vs fair value
Close $354.00200-day averageGekko Fair Value $438.84
Cencora quick facts
- Market cap
- $67.55B
- P/E ratio
- 24.6
- Forward P/E
- 16.6
- EPS, TTM
- $13.76
- Revenue, TTM
- $332.8B
- Profit margin
- 0.8%
- Dividend yield
- 0.71%
- Beta
- 0.57
- Volume
- 2.89M avg 1.29M
- 1-year return
- +3.8%
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±4.7%
- 50-day average
- $324.63
- 200-day average
- $316.94
- Next earnings
- —
- Shares outstanding
- 190.8M
Cencora swing-trade checklist
Cencora scores 4 supportive, 0 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $354.00 is above the 50-day ($324.63) and 200-day ($316.94) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexheadwind
43.1, Distribution
Reading 43.1 is in the Distribution zone.
See the GekkoIndex - Fair valuesupportive
19.3% below
Price is 19.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart money - Earnings riskno data
No data
No confirmed report date on the calendar.
See earnings - Seasonalitysupportive
+1.3% on average
From this point in the calendar, the next 20 trading days averaged +1.3% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Cencora stock chart and price history
Cencora closed at $354.00 on Nov 4, 2026, +3.8% over the past year, inside a 52-week range of $244.82 to $377.54.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +11.9%
- 3 months
- +8.9%
- 6 months
- +40.1%
- 1 year
- +3.8%
The full COR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open COR in Gekko
Follow Cencora through every session
Put COR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track COR in GekkoFree for 7 days. No credit card required.
About Cencora
Cencora sources and distributes pharmaceutical products across the United States and international markets. Through its U.S. Healthcare Solutions segment, it supplies generic and injectable medications, over-the-counter health items, and home healthcare equipment, along with specialized products such as plasma, blood derivatives, and vaccines. The company is also known for its work in animal health, offering pharmaceuticals, vaccines, parasiticides, diagnostics, and feed ingredients for companion and production animals.
Cencora's customers include acute care hospitals, health systems, retail and mail-order pharmacies, medical clinics, oncologists, dialysis clinics, and other healthcare providers. Beyond product supply, it provides pharmacy management, staffing, and consulting services, builds supply management software, handles packaging for institutional and retail healthcare settings, and supports clinical trials, post-market approval, and commercialization for biotechnology and pharmaceutical manufacturers, including data analytics and outcomes research. Its International Healthcare Solutions division handles global pharmaceutical wholesale operations, commercialization support, and logistics for the biopharmaceutical sector, reaching pharmacies, doctors, health centers, and hospitals abroad.
The company traces back to 1871 and was previously named AmerisourceBergen Corporation before taking the name Cencora in August 2023. It is headquartered in Conshohocken, Pennsylvania, and its shares are listed on the NYSE under the ticker COR.
- Listed
- NYSE
- Sector
- Distribution services
- Industry
- Medical distributors
- Website
- cencora.com
Cencora GekkoIndex: the smart money zone
Cencora’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 43.1, in the Distribution zone, down 16.1 points over five sessions.
43.1Distribution
Down 16.1 points over five sessions, from the Neutral zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 27 | −0.5% | +4.6% | ||
| Accumulation | 181 | +0.6% | +2.5% | ||
| Neutral | 424 | +0.5% | +0.8% | ||
| Distribution (current zone) | 63 | −0.6% | +0.2% | ||
| Selling | 2 | Too few readings yet | |||
Average COR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the COR price, zone by zone.Track COR in Gekko
Is Cencora stock overvalued? Gekko Fair Value
Cencora trades 19.3% below Gekko Fair Value of $438.84, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Cencora shares are worth, recalculated every trading day.
$438.84
Gekko Fair Value, Nov 4, 2026
19.3% Undervalued
At the end of Aug 2026 the price was 31.7% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open COR in Gekko
Cencora insider and Congress trading
No open-market insider purchases were filed for Cencora, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 4 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Cencora has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $1.00B
- As a share of market cap
- 1.48%
From company filings.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold COR.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Cencora earnings: next date and track record
Cencora beat the EPS estimate in 8 of its last 8 reports, moving 5.6% on average across the report.
8 of 8reports beat the EPS estimate
±5.6%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- Cencora reported solid fiscal Q3 2026 results driven by strong execution in U.S. Healthcare Solutions (notably specialty, MSOs RCA and OneOncology) and International growth. Consolidated revenue was $84.8 billion, up 5%; consolidated adjusted gross profit increased 23% and adjusted gross margin expanded to 4.16%. Adjusted operating income grew 17% and adjusted EPS rose 12% (helped by $1 billion opportunistic share repurchases). Management raised fiscal 2026 adjusted EPS guidance and highlighted continued investments in specialty, digital transformation, and talent. OneOncology outperformed expectations and is expected to be roughly EPS neutral on a 12-month basis net of financing; accounting treatment for a UUG noncontrolling interest was clarified with no operating income impact. Management emphasized the long-term opportunity across MSOs, clinical trials, and specialty logistics (World Courier / 3PL) while noting continued monitoring of policy/regulatory initiatives (340B, ASP/GLOBE demo).
- Guidance
- Raised fiscal 2026 adjusted EPS guidance to $17.75 - $17.95. Q4 guidance implies strong double-digit growth across reportable segments at the midpoint. OneOncology is expected to be neutral to adjusted EPS on a 12-month basis net of financing. Management will provide 2027 outlook on the November call.
- Risks flagged
- Policy and regulatory uncertainty (340B program changes, proposed ASP rule changes / GLOBE demonstration) that could affect reimbursement and physician economics; competitive dynamics in specialty logistics/3PL; customer-specific dynamics (losses or in-sourcing by large customers); timing effects and accounting items (held-for-sale accounting impacts); general market and utilization variability in specialty and oncology.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $4.48 est $4.37 | $84.75B est $84.31B | +6.1% |
| May 6, 2026 | $4.75 est $4.73 | $78.36B est $81.09B | −16.4% |
| Feb 4, 2026 | $4.08 est $4.05 | $85.93B est $86.06B | −2.7% |
| Nov 5, 2025 | $3.84 est $3.79 | $83.73B est $83.46B | +4.6% |
| Aug 6, 2025 | $4.00 est $3.85 | $80.66B est $80.09B | −4.8% |
| May 7, 2025 | $4.42 est $4.11 | $75.45B est $75.68B | −2.4% |
| Feb 5, 2025 | $3.73 est $3.52 | $81.49B est $78.31B | −2.2% |
| Nov 6, 2024 | $3.34 est $3.22 | $79.05B est $77.62B | +5.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Cencora stock forecast and analyst price targets
Analysts’ average 12-month price target for Cencora is $371.67, +5.0% from the last close, from 13 firms rating the stock in the last 90 days.
$371.67consensus 12-month target, +5.0% from the last close
Now $354.00Avg $371.67
Low $330High $400
Each firm’s latest rating in the last 90 days: 13 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 22 | Robert W. Baird | $375 | +5.9% |
| Oct 21 | Bank of America Securities | $345 | −2.5% |
| Oct 20 | Argus Research | $380 | +7.3% |
| Oct 16 | UBS | $400 | +13.0% |
| Oct 7 | Leerink Partners | $388 | +9.6% |
+0.2%average 20-day move after past Distribution readings
+1.3%average move over the next 20 trading days in the last 5 years
±2.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Cencora seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Cencora averaged +1.3% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.5% | 3 of 5 |
| Next 10 trading days | +1.4% | 3 of 5 |
| Next 15 trading days | +3.0% | 4 of 5 |
| Next 20 trading days | +1.3% | 3 of 5 |
| Next 30 trading days | +0.3% | 2 of 5 |
For scale, COR’s typical 20-trading-day move in either direction is about 4.7%.
Cencora market cap and key statistics
Cencora’s market cap is $67.55B, with a P/E ratio of 24.6 and revenue of $332.8B over the last twelve months.
Valuation
- Market cap
- $67.55B
- P/E ratio
- 24.6
- Forward P/E
- 16.6
- EPS, TTM
- $13.76
- Gekko Fair Value
- $438.84
Trading
- Volume
- 2.89M
- Avg volume, 20 days
- 1.29M
- 52-week high
- $377.54
- 52-week low
- $244.82
- Shares outstanding
- 190.8M
Financials
- Revenue, TTM
- $332.8B
- Profit margin
- 0.8%
- Return on equity
- 96.9%
- Quarterly earnings growth, YoY
- +11.9%
Risk and income
- Beta
- 0.57
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±4.7%
- Dividend yield
- 0.71%
Cencora stock news this week
Coverage of Cencora this week reads positive: 10 positive, 9 neutral and 1 negative headlines.
- Cencora FY27 EPS guidance misses estimate at $19.40-$19.75scanx.trade, Nov 4
- Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins ExpandTradingView, Nov 4
- Cencora, Inc. (COR) Q4 2026 Earnings Call TranscriptSeeking Alpha, Nov 4
- Stock replaces a $35,000 cash retainer for Cencora (COR) director Dennis M. Nally.Stock Titan, Nov 4
- Form 8K Cencora Inc For: 4 November By Investing.comInvesting.com Canada, Nov 4
- Cencora (COR) director Ellen Cooper receives 91 stock units instead of a $30,000 cash retainer.Stock Titan, Nov 4
Cencora peers
Cencora’s 3 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| MCKMcKesson | Distribution | 1.7% above |
| CAHCardinal Health | Neutral | 35.1% below |
| HSICHenry Schein | Neutral | 6.6% above |
A peer links to its own page where one exists.
Cencora stock FAQ
What is Cencora’s market cap?
Cencora’s market cap is $67.55B at the Nov 4, 2026 close of $354.00, with 190.8M shares outstanding. The shares trade on a P/E ratio of 24.6.
What is the Cencora stock forecast?
The consensus analyst 12-month price target for Cencora is $371.67, +5.0% from the last close. Of the 13 firms that rated the stock in the last 90 days, 11 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Cencora stock overvalued or undervalued?
On Gekko’s estimate Cencora is undervalued: the Nov 4, 2026 close of $354.00 is 19.3% below Gekko Fair Value of $438.84. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
What is Cencora’s 52-week high and low?
Cencora’s 52-week high is $377.54 and its 52-week low is $244.82; it closed at $354.00 on Nov 4, 2026, +3.8% over the past year.
Is Cencora stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (trend, fair value, smart money and seasonality) and 1 as a headwind (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Cencora the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.